Kwality Pharmaceuticals Receives CDSCO Nod to Initiate Preclinical Pilot Batches of Pembroluzimab
Kwality Pharmaceuticals Limited has achieved a major milestone in its biologics development journey after receiving permission from the Central Drugs Standard Control Organization (CDSCO). The approval allows the company to manufacture pilot batches of Pembroluzimab for preclinical studies.The CDSCO granted this authorization following a thorough review of the product's development data submitted by the Company's R&D team. This clearance marks a critical transition for the drug, moving it from the research and development stage into the Pre-Clinical stage.
The approval signifies Kwality Pharmaceuticals’ advancement in developing biologics treatments. The company aims to be among the first wave of generic manufacturers to launch Pembroluzimab once the reference product's patent expires, contingent upon successful development and achieving all necessary regulatory approvals.
KPL Stock Price Movement
Edging closer to its intraday high, shares of Kwality Pharmaceuticals Limited gain by 0.42% as of 10:08 AM, trading at ₹2683.4. The stock trades within an intraday range, showing solid support after dipping down to ₹2664 and nearing the daily peak at ₹2739.90.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.